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Abstract
Background: Growth-differentiation factor-15 (GDF-15) is an emerging humoral marker for risk stratification in
cardiovascular disease. Cardiac-surgery-associated acute kidney injury (CSA-AKI), an important complication in
patients undergoing cardiac surgery, is associated with poor prognosis. The present secondary analysis of an
observational cohort study aimed to determine the role of GDF-15 in predicting CSA-AKI compared with the
Cleveland-Clinic Acute Renal Failure (CC-ARF) score and a logistic regression model including variables associated
with renal dysfunction.
Methods: Preoperative plasma GDF-15 was determined in 1176 consecutive patients undergoing elective cardiac
surgery. Patients with chronic kidney disease stage 5 were excluded. AKI was defined according to Kidney-
Disease-Improving-Global-Outcomes (KDIGO) - creatinine criteria. The following variables were screened for
association with development of postoperative AKI: age, gender, additive Euroscore, serum creatinine, duration of
cardiopulmonary bypass, duration of surgery, type of surgery, total circulatory arrest, preoperative hemoglobin,
preoperative oxygen-supplemented cerebral oxygen saturation, diabetes mellitus, hemofiltration during ECC,
plasma GDF-15, high sensitivity troponin T (hsTNT), and N-terminal prohormone of B-type natriuretic peptide
(NTproBNP).
Results: There were 258 patients (21.9 %) with AKI (AKI stage 1 (AKI-1), n = 175 (14.9 %); AKI-2, n = 6 (0.5 %); AKI-3,
n = 77 (6.5 %)). The incidence of AKI-1 and AKI-3 increased significantly from the lowest to the highest tertiles of
GDF-15. In logistic regression, preoperative GDF-15, additive Euroscore, age, plasma creatinine, diabetes mellitus,
and duration of cardiopulmonary bypass were independently associated with AKI. Inclusion of GDF-15 in a
logistic regression model comprising these variables significantly increased the area under the curve (AUC 0.738
without and 0.750 with GDF-15 included) and the net reclassification ability to predict AKI. Comparably, in receiver
operating characteristic analysis the predictive capacity of the CC-ARF score (AUC 0.628) was improved by adding
GDF-15 (AUC 0.684) but this score also had lower predictability than the logistic regression model. In random forest
analyses the predictive capacity of GDF-15 was especially pronounced in patients with normal plasma creatinine.
Conclusion: This suggests that preoperative plasma GDF-15 independently predicts postoperative AKI in patients
undergoing elective cardiac surgery and is particularly helpful for risk stratification in patients with normal creatinine.
Trial registration: NCT01166360 on July 20, 2010.
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Background
Cardiac-surgery-associated acute kidney injury (CSA-
AKI) is an important and frequent complication in pa-
tients undergoing cardiac surgery and associated with
increased morbidity and short-term and long-term mor-
tality [1]. The incidence of CSA-AKI is variable and de-
pends on the definition used, but has been reported to
be as high as 40 % according to the Acute Kidney Injury
Network (AKIN) criteria [2]. CSA-AKI requiring tem-
porary renal replacement therapy occurs in up to 30 %
of patients and has been associated with a mortality rate
up to 60 % [1, 3].
No specific treatment for the prevention of CSA-AKI
is available [4]. This may be related to the multifactorial
pathophysiology of this complication [5], including post-
operative factors that are difficult to predict preopera-
tively [6], but also to the fact that sparse modalities for
preoperative risk stratification are available and that
commonly used risk scores have variable prognostic util-
ity in this regard [7]. However, preoperative identifica-
tion of patients with a high risk of developing CSA-AKI
is a prerequisite for developing strategies to ameliorate
or prevent perioperative renal injury.
Very recently, two studies in 32 and 134 patients, re-
spectively, provided evidence that the preoperative
plasma level of the hormone growth-differentiation
factor-15 (GDF-15) predicts postoperative renal injury
[8, 9] in patients undergoing coronary artery bypass graft
(CABG). We have previously shown that the preopera-
tive plasma concentration of GDF-15 is an independent
predictor of morbidity and short-term and long-term
mortality in patients undergoing cardiac surgery [10].
The present study aims to confirm the findings of
the pilot studies [8, 9] in a larger and heterogenous
patient cohort to determine if this hormone may also
be used for assessing the risk of developing AKI in
this population.
Methods
The present study is a secondary analysis of a large pro-
spective observational cohort study analyzing the prognos-
tic relevance of preoperative cerebral oxygen saturation
and markers of cardiopulmonary dysfunction with respect
to clinical outcomes in patients undergoing cardiac sur-
gery [10, 11]. In total 2009 patients were screened during
the study period between January and December 2008 and
April to December 2009. There were 5 patients who re-
fused to participate in the study, and 76 patients had their
surgery cancelled. Complete datasets including GDF-15
measurements were available from 1458 patients and used
for the previously published analyses [10]. Excluding
emergency patients, off-pump revascularization, interven-
tional procedures, and patients with chronic kidney dis-
ease stage 5, plasma samples for determination of plasma
GDF-15 were available from 1176 consecutive patients
undergoing elective cardiac surgery, and these were used
for the present analysis.
The primary objective was to determine the relation-
ship between preoperative plasma GDF-15 and AKI [12]
in comparison with the Cleveland Clinic acute renal fail-
ure (CC-ARF) score [13] and a comprehensive logistic
regression model based on variables typically associated
with AKI in patients undergoing cardiac surgery, to in-
vestigate whether GDF levels can further improve risk
stratification for AKI.
Plasma samples for determination of GDF-15 were
taken immediately preoperatively (before induction of
anesthesia) and determined as described recently [10].
Plasma was separated and stored at -80 °C for further
analysis. Analyses were accomplished within 6 months
after completion of enrollment by electrochemilumines-
cence immunoassays using Elecsys 2010 analyzers
(Roche Diagnostics, Mannheim, Germany).
Plasma creatinine was measured the day before surgery.
Postoperative AKI was graded according to the Kidney
Disease Improving Global Outcomes (KDIGO) - creatin-
ine criteria, [12] from maximal postoperative plasma cre-
atinine in relation to the preoperative baseline, and from
the need for renal replacement therapy (for grade 3 AKI).
Cardiac surgery was performed with cardiopulmonary
bypass (CPB) during moderate hypothermia. Surgical,
anesthetic and CPB management have been described
elsewhere [6, 10, 11]. Shortly, general anesthesia was in-
duced with propofol and sufentanil, and before and after
CPB was maintained with remifentanil and sevoflurane.
During CPB, anesthesia was maintained with remifentanil
and propofol. Perioperative fluid therapy was performed
with balanced cristalloid solutions (Sterofundin ISO®,
B.Braun, Melsungen, Germany) and 6 % hydroxyethyl
starch 130/0.4 (Voluven®) (Fresenius Kabi, Bad Homburg,
Germany). The CPB was primed with cristalloid.
Statistical analyses
Analyses were performed with R version 3.2.2 (Develop-
ment Core Team; 2015 R: a language and environment for
statistical computing. R Foundation for Statistical Com-
puting, Vienna, Austria. ISBN 3-900051-07-0, http://
www.R-project.org/. Accessed 18 Sept 2016). Data are pre-
sented as mean ± SD if normally distributed or otherwise
as median and 25 and 75 % quartiles. Comparisons be-
tween groups for univariate predictors of outcome were
performed using the two-sided chi-square test for categor-
ical variables and the Mann-Whitney or Kruskal-Wallis
test for continuous variables, where appropriate.
The following variables were screened for association
with the development of postoperative AKI: age, gender,
additive Euroscore, serum creatinine, duration of CPB,
duration of surgery, type of surgery, total circulatory
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arrest, preoperative hemoglobin level, preoperative oxy-
gen supplemented cerebral oxygen saturation (ScO2),
diabetes mellitus, hemofiltration during CPB, plasma
GDF-15, high sensitivity troponin T (hsTNT), and N-
terminal prohormone of B-type natriuretic peptide
(NTproBNP).
The association between the aforementioned variables
and the development of CSA-AKI was investigated using
logistic regression and machine learning techniques.
Model building and variable selection was performed
using computer intensive methods (bootstrap aggrega-
tion) [14]. In order to investigate nonlinear effects and
complex interactions among variables, machine learning
methods were utilized (random forests and recursive
partitioning using conditional inference trees) [15]. Vari-
able importance (VIMP) and minimal tree depth was
used to access the strength of association between each
predictor and the development of AKI. Net reclassifica-
tion improvement and integrated discrimination im-
provement to assess the additive predictive ability of
GDF-15 on the development of AKI were calculated as
described by Pencina et al. [16]. Comparisons between
receiver-operating characteristic (ROC) curves were per-
formed by the DeLong method and the bootstrap
method. The p values (two-tailed) for the DeLong
method are presented. Statistical significance was
assessed at the 5 % level (p < 0.05 was considered statisti-
cally significant).
Results
Postoperative AKI was observed in 258 patients (21.9 %)
(AKI stage 1 (AKI-1), n = 175 (14.9 %); AKI-2, n = 6
(0.5 %); AKI-3, n = 77 (6.5 %)). The incidence of AKI-1
and AKI-3 increased significantly from the lowest to the
highest tertiles of GDF-15 (Table 1). Accordingly, pre-
operative plasma GDF-15 was significantly higher in re-
lation to the severity of AKI in comparison with patients
without this complication (Fig. 1).
Preoperative, operative, and postoperative characteris-
tics are presented in Table 1, showing that patients in
the highest GDF-15 tertile also had a significantly in-
creased risk profile.
The odds ratio from the final logistic regression model,
which included GDF-15, was 1.314 (95 % CI 1.142,
1.551; p = 0.001), with bootstrap reliability of 95.4 %.
Preoperative plasma GDF-15 was independently and sig-
nificantly associated with the postoperative development
of CSA-AKI. This was not the case for NTproBNP and
hsTNT. The full model is presented in Table 2. To fur-
ther elucidate the effects of adding GDF-15 to the multi-
variate model, the probability of AKI for a prototype
patient is graphically displayed in Fig. 2.
In logistic regression analysis , GDF-15 was compar-
ably and significantly associated with 30-day mortality
(Additional file 1: Table S1). The ROC analysis of the
CC-ARF score and the final logistic regression model -
with and without the inclusion of GDF-15 - as a pre-
dictor variable is presented in Fig. 3a and b. In ROC
analyses the CC-ARF score had only moderate predictive
capacity (area under the curve (AUC) 0.628) for AKI-1
to AKI-3, which was increased by adding GDF-15 (AUC
0.684; p < 0.001). Our logistic regression model investi-
gating the association between preoperative factors and
all forms of postoperative AKI (AKI-1 to AKI-3) pro-
duced an AUC of 0.738, which was significantly in-
creased (p < 0.001) to 0.750 by adding GDF-15 (p =
0.014).
On analysis restricted to the outcome postoperative
AKI-3, the CC-ARF score alone had an AUC of 0.747,
which was increased by GDF-15 to 0.795 (p < 0.001). In
contrast the AUC of our clinical regression model for
AKI 3 was 0.827, which was improved (p = 0.04) to an
AUC of 0.848 by incorporating GDF-15. Such improve-
ment in risk stratification was not observed in predicting
AKI-1, as the addition of GDF-15 did not improve the
AUC for AKI-1 (Fig. 4).
Reclassification analysis revealed that the addition of
GDF-15 in the logistic regression model led to a statisti-
cally significant increase in the net reclassification abil-
ity. The reclassification analysis and tables are presented
in Table 3.
Random forest analysis showed that patient age, pre-
operative creatinine and preoperative plasma GDF-15
were the three most important variables associated with
the development of CSA-AKI (Additional file 2: Figure
S1). There was significant non-linearity and interactions
of predictor variables in the incidence of AKI. As
depicted in Additional file 3: Figure S2, within the same
additive Euroscore category (panel row), increases in
GDF (columns from left to right) are associated with in-
crease in probability for CSA-AKI. As shown, this is es-
pecially pronounced in patients with creatinine levels
<180 μmol/l. In addition, recursive partitioning revealed
the important role of GDF-15 and specific plasma levels
of this hormone stratified according to other independ-
ent risk factors (Fig. 5).
Discussion
Several mechanisms mediating a perioperative decrease
in renal function have been identified within recent
years and several biomarkers have been proposed to
facilitate early detection of AKI, i.e., neutrophil-
gelatinase-associated lipocalin (NGAL), kidney-injury
molecule -1 (KIM-1), liver-type fatty acid binding protein
(L-FABP), interleukin-18 (IL-18), insulin-like growth
factor-binding protein 7 (IGFBP7), and tissue inhibitor of
metalloproteinase (TIMP-2) [17]. However, these bio-
markers are intended for the early detection of AKI after a
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renal insult has occurred and not for preoperative risk
stratification.
Extending the observations of two recent pilot studies
in patients undergoing CABG [8, 9], the findings of the
present study again show that preoperative plasma GDF-
15 is an independent predictor of postoperative renal
dysfunction in a heterogeneous population of patients
undergoing elective cardiac surgery.
GDF-15, also entitled macrophage inhibitory cytokine-
1 (MIC-1) is a cytokine expressed in many tissues, in-
cluding myocardium, lung, kidney, brain, liver, and the
intestine, upon various stimuli, including myocardial
Table 1 Demographics, preoperative, operative and postoperative characteristics of the patient population according to tertiles of
preoperative growth-differentiation factor-15
GDF tertile 1 GDF tertile 2 GDF tertile 3 Total P value
N 392 392 392 1176
Male 282 (71.9 %) 272 (69.4 %) 256 (65.3 %) 810 (68.9 %) 0.129
Age (years) 59 (50/67) 69 (63/74) 72 (67/77) 68 (50/74) <0.001
NYHA I 161 (41.1 %) 137 (34.9 %) 113 (28.8 %) 411 (34.9 %) 0.002
NYHA II 104 (26.5 %) 97 (24.7 %) 87 (22.2 %) 288 (24.5 %) 0.365
NYHA III 111 (28.3 %) 138 (35.2 %) 146 (37.2 %) 395 (33.6 %) 0.021
NYHA IV 15 (3.8 %) 19 (4.8 %) 44 (11.2 %) 78 (6.6 %) <0.001
Additive Euroscore 3 (2/6) 5 (3/7) 7 (5/8) 5 (3/7) <0.001
GDF-15 (ng/ml) 0.643 (0.535/0.730) 0.991 (0.914/1.114) 1.731 (1.438/2.329) 0.989 (0.729/1.435) <0.001
NTproBNP (pg|ml) 187.8 (74.4/495.0) 427.9 (155.4/900.6) 1044.6 (383.4/2528.7) 434.5 (137.8/1139.3) <0.001
hsTNT (pg/ml) 6.3 (3.0/11.1) 11.4 (6.6/18.8) 20.4 (12.0/38.0) 11.4 (5.6/21.5) <0.001
ScO2minox (%) 68 (63/72) 65 (60/70) 63 (57/67) 65 (60/70) <0.001
Diabetes mellitus (n (%)) 152 (38.8 %) 250 (63.8 %) 305 (77.8 %) 707 (60.1 %) <0.001
LVEF 1 (n (%)) 6 (1.5 %) 10 (2.6 %) 24 (6.1 %) 40 (3.4 %) <0.001
LVEF 2 (n (%)) 57 (14.5 %) 74 (18.9 %) 102 (26.0 %) 233 (19.8 %) <0.001
LVEF 3 (n (%)) 328 (36.4 %) 307 (34.1 %) 266 (29.5 %) 901 (76.8 %) <0.001
Reoperation (n (%)) 28 (7.1 %) 35 (8.9 %) 48 (12.2 %) 111 (9.4 %) 0.046
Creatinine (μmol/l) 73.9 (65.1/83.6) 82.7 (68.6/93.3) 93.3 (76.6/117.0) 81.0 (68.6 /96.8) <0.001
eGFR (MDRD) (ml/min/m2) 94.2 (80.1/110.5) 80.7 (66.8/95.1) 66.2 (49.5/83.4) 80.9 (64.7/98.9)) <0.001
Hemoglobin (g/l) 139 (130/148) 135 (125/145) 129 (115/140) 135 (124/144) <0.001
Peripheral vascular disease (n (%)) 45 (11.5 %) 45 (11.5 %) 47 (12.0 %) 137 (11.6 %) 0.967
CPB time (minutes) 108 (86/144) 109 (84/135) 114 (92/149) 110 (88/142) 0.027
DHCA (n (%)) 19 (4.8 %) 8 (2.0 %) 3 (0.8 %) 30 (2.6 %) 0.001
IOP hemofiltration (n (%)) 12 (3.0 %) 12 (3.0 %) 36 (9.2 %) 60 (5.1 %) <0.001
Isolated CABG (n (%)) 173 (44.1 %) 199 (50.8 %) 164 (41.8 %) 536 (45.6 %) 0.033
Mitral valve surgery (n (%)) 36 (9.2 %) 55 (14.0 %) 83 (21.2 %) 174 (14.8 %) <0.001
Aortic valve surgery (n (%)) 161 (41.1 %) 133 (33.9 %) 161 (41.1 %) 455 (38.7 %) 0.06
MAZE (n (%)) 19 (4.8 %) 31 (7.9 %) 53 (13.5 %) 103 <0.001
HDU LOS (days) 2 (2/4) 3 (2/5) 4 (2/7) 3 (2/5) <0.001
AKI 1 37 (9.4 %) 53 (13.5 %) 85 (21.7 %) 175 (14.9 %) <0.001
AKI 2 3 (0.76 %) 1 (0.26 %) 2 (0.51 %) 6 (0.51 %) 0.65
AKI 3 4 (1.0 %) 17 (4.3 %) 56 (14.3 %) 77 (6.54 %) <0.001
Renal replacement therapy 4 (1 %) 17 (4.3 %) 55 (14.3 %) 77 (6.45 %) <0.001
30-day mortality 2 (0.5 %) 4 (1 %) 17 (4.4 %) 23 (1.96 %) <0.001
NYHA New York Heart Association grade of heart failure, NTproBNP N-terminal pro-hormone of the B-type natriuretic peptide, hsTNT high-sensitivity troponine-T,
LVEF left ventricular ejection fraction (1: <30 % or severely reduced; 2: 30–50 % or moderately reduced; 3: ≥50 % or normal), MDRD creatinine clearance according to
the Modifications of Diet in Renal Disease formula, CPB cardiopulmonary bypass time, DHCA deep hypothermic circulatory arrest,
IOP-hemofiltration intraoperative hemofiltration during CPB, CABG coronary artery bypass graft, MAZE MAZE - procedure; HDU LOS high-dependency unit time
(intensive care and intermediate care unit), AKI 1 to AKI 3 acute kidney injury according to KDIGO creatinine criteria
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stretch, volume overload, experimental cardiomyopathy
and oxidative stress, other inflammatory cytokines, and
ischemia/reperfusion (for a detailed overview see [18]).
However, the physiological role of this peptide in the
cardiovascular system still remains to be defined.
Our group has recently shown that preoperative
plasma GDF-15 is an independent predictor of postop-
erative mortality and morbidity in patients undergoing
cardiac surgery and can further stratify patients beyond
the established risk scores such as the Euroscore, and
other cardiovascular risk markers such as NTproBNP
or hsTNT [10]. The present analysis extends these find-
ings to the prediction of CSA-AKI, an important com-
plication in patients undergoing cardiac surgery, which
is associated with poor short-term and long-term prog-
nosis [1].
Employing logistic regression modeling of variables
with an established (age, gender, additive Euroscore,
serum creatinine, duration of CPB, duration of surgery,
type of surgery, total circulatory arrest, preoperative
hemoglobin, and diabetes mellitus) or putative (ScO2,
hemofiltration during ECC, plasma GDF-15, hsTNT,
and NTproBNP) role as risk factors for CSA-AKI, we
observed that GDF-15 is an independent predictor of
CSA-AKI and confirmed this finding using multiple stat-
istical methods. It is of note that in random forest ana-
lysis the ability of GDF-15 to predict CSA-AKI was
especially pronounced in patients with normal plasma
creatinine; one explanation why this hormone had su-
perior predictive ability in comparison with a conven-
tional risk score like the additive Euroscore in our
previous study [10]. Additionally, the observation that
NTproBNP and hsTNT - despite being widely accepted
biomarkers of cardiopulmonary dysfunction – did not
predict AKI, further supports the powerful potential of
GDF-15 for risk stratification in this regard. It is of note
that the risk prediction potential of GDF-15 was primar-
ily related to the ability to predict AKI-3. Whether this
Fig. 1 Plasma growth-differentiation factor-15 (GDF-15) in patients without acute kidney injury (AKI) and in patients with AKI grade 1 (AKI-1) and
grade 3: *analysis of variance; p < 0.001). Preoperative plasma GDF-15 was significantly higher in relation to the severity of AKI in comparison with
patients without this complication (no AKI vs. Grade 1, p < 0.001; Grade 1 vs Grade 3, p < 0.001)
Table 2 Final logistic regression model specification for any grade of acute kidney injury
Factor Odds ratio 95 % CI P value Bootstrap reliability
Intercept 0.002 0.0006, 0.007 <0.001 99.8 %
GDF-15 (ng/ml) 1.314 1.142, 1.551 <0.001 95.4 %
Age (years) 1.039 1.021, 1.058 <0.001 98.9 %
Additive Euroscore 1.074 1.009, 1.143 0.02 71.3 %
Creatinine (μmol/l) 1.007 1.002, 1.011 0.003 79.0 %
Diabetes mellitus 1.362 0.981, 1.881 0.06 50.1 %
CPB time (minutes) 1.006 1.003, 1.009 <0.001 96.6 %
For any increase in growth-differentiation factor-15 (GDF-15) of 1 ng/ml the odds ratio for developing acute kidney injury of is 1.34. CPB cardiopulmonary bypass
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may be related to the physiology or pathophysiology of
GDF-15 or that AKI-1 events are very difficult to predict
remains speculative.
Various clinical scores for the prediction of renal dys-
function after cardiac surgery have been developed
within recent years and these have highly variable pre-
dictive ability [7]. We tested the CC-ARF score as one of
the most popular scores [13]. As expected, the predictive
ability of this score, which was primarily developed to
predict postoperative need of dialysis (that renders
patients AKI stage 3), was rather poor if used to predict
any type of AKI. However, when combined with GDF-
15, the predictive ability was markedly improved for any
kind of AKI and especially for AKI-3, as the most severe
stage of postoperative renal dysfunction. This may have
clinical relevance, because the CC-ARF score - in con-
trast to our model - has been externally validated and is
widely used [13].
Very recently, Bignami and coworkers [19] reported
that the preoperative plasma level of the endogeneous
Fig. 2 Probability of a prototypical patient aged 65 years with an additive Euroscore of 5.15, and a duration of cardiopulmonary bypass of 123 minutes
for a range of creatinine values (x-axis) and the 5 and 95 % quantiles of growth-differentiation factor-15 (GDF-15) (0.467 and 2.770, respectively) as
derived from the multivariate model. AKI acute kidney injury, CC-ARF Cleveland Clinic Acute Renal Failure (score)
Fig. 3 Receiver operator characteristics of the Cleveland clinic acute renal failure (CC-ARF) score [13] and nested logistic regression models on the
development of cardiac-surgery-associated acute kidney injury (CSA-AKI) with and without taking into account preoperative plasma levels of
growth-differentiation factor-15 (GDF). a Analyses for any stage of AKI (i.e., AKI-1 to AKI-3). b Analysis restricted AKI-3 only. The inclusion of GDF in
the models led to statistically significant (analysis of variance; p < 0.001) predictive ability (either CC-ARF or a model based on additive Euroscore,
age, plasma creatinine, diabetes mellitus, and duration of cardiopulmonary bypass). AUC area under the curve
Heringlake et al. Critical Care  (2016) 20:317 Page 6 of 10
hormone ouabain is an independent predictor of AKI in
a derivation and a validation cohort of patients undergo-
ing cardiac surgery, and that it improves the predictive
ability of a clinical risk score for AKI. It is of note that
ouabain and GDF-15 both reflect circulatory stress [20,
21], supporting the role of this factor as a trigger of AKI
in this setting. But there are also relevant discrepancies
between the two peptides. First of all, Bignami et al. pro-
vided experimental data for a pathophysiological link be-
tween increased circulating levels of ouabain and
decreased renal function (i.e., decreased creatinine clear-
ance, increased urinary protein excretion, and reduced
podocyte nephrin) [19], whereas a direct detrimental ef-
fect of increased GDF-15 levels on renal function has
not been shown so far. In contrast, some lines of evi-
dence point to a protective role of GDF-15 in diabetic
nephropathy [22].
Additionally, Bignami et al. [19] employed a more
rigorous definition of AKI (AKI grade 2 and 3) than we
did. However, restricting our analyses to AKI-3 we also
observed a numerically almost comparable and relevant
increase in the AUC in ROC analysis by adding GDF-15
to our logistic regression model. Future studies need to
determine which of these peptides has the better power
to predict for all stages and the most severe forms of
AKI.
Limitations
The present study has several limitations. First, this is a
secondary analysis of a monocentrical, observational
study primarily aiming to determine the association be-
tween GDF-15 and postoperative morbidity and mortal-
ity. Consequently, as we have shown that there is such
an association (i.e., that preoperative GDF-15 is an inde-
pendent marker of morbidity and mortality in this co-
hort of patients [10]) it cannot be ruled out completely
that the described association between preoperative
GDF-15 and AKI is epiphenomenal. This may also be
true for the observed association of a higher clinical risk
profile and GDF-15 tertiles and the observation, that -
also in this cohort of patients undergoing elective sur-
gery - GDF-15 was an independent predictor of 30-day
mortality. With respect to the high mortality in AKI [1],
cross-correlation between these two outcomes is almost
inevitable. However, the results of the random forest
analysis - showing that GDF-15 is especially useful for
predicting AKI in patients with low plasma creatinine
and who do not typically have a high risk profile -
Fig. 4 Receiver operator characteristics of nested logistic regression models on the development of cardiac-surgery-associated acute kidney injury
(CSA-AKI) with and without (w/o) taking into account preoperative plasma levels of growth-differentiation factor-15 (GDF) for acute kidney injury
(AKI) grade 1 and 3. While the inclusion of GDF led to a statistically significant increase in the area under curve (AUC) for AKI grade 3, this was not
the case for AKI grade 1
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indicates that there are subgroups of patients in whom
such an epiphenomenal association is at least not
obvious.
As a second point one may argue that the improve-
ments in the clinical models by incorporating GDF-15
were numerically small and despite being statistically
significant, they may be of questionable clinical rele-
vance. Nonetheless, the reclassification analyses clearly
show that the net effect of reclassification taking into ac-
count GDF-15 levels in comparison with the logistic re-
gression model alone was much more pronounced than
suggested by the small differences in the AUC [16].
Third, the CC-ARF score had significantly lower ability
to predict AKI-1 to AKI-3 and AKI-3 alone than logistic
regression analysis based on the present cohort. This con-
trasts with some studies showing excellent prediction of
AKI using the CC-ARF score [7, 13] This, however may at
least in part be explained by the fact that the present co-
hort consisted only of patients undergoing elective sur-
gery, as emergency patients were excluded. Thus, the
difference between our model and the CC-ARF score may
be less pronounced during real-life conditions.
Additionally, we classified AKI only according to cre-
atinine criteria, because data on urine flow were only
available for patients studied in 2009. This may lead to
discrepancies in comparison with studies analyzing the
predictability of renal risk scores based on the analysis
of creatinine and urine flow. Recent data from critically
ill patients [23] and patients undergoing cardiac surgery
[24] clearly suggest that the omission of urine flow may
have led to underestimation of the incidence of AKI.
However, patients diagnosed with AKI according to cre-
atinine criteria seem to have a much worse prognosis,
i.e., higher mortality [23, 24]. Consequently, AKI diagno-
sis based only on creatinine criteria may be regarded as
more conservative and helpful in identifying those pa-
tients with renal dysfunction who have the highest mor-
tality risk.
Fourth, despite confirmation of findings from smaller
pilot studies by the present analysis, definitive con-
firmation of the role of GDF-15 for predicting AKI
mandates further and multicenter prospective trials.
Ideally, these studies should specifically address dia-
betes mellitus as a potential confounder, because
Table 3 Reclassification analysis
Outcome: absent
Updated model (risk categories)
Initial model (risk categories) (0, 0.01) (0.01, 0.05) (0.05, 0.1) (0.1, 1) % reclassified
(0, 0.01) 0 0 0 0 -
(0.01, 0.05) 0 53 2 0 4
(0.05, 0.1) 0 12 143 13 15
(0.1, 1) 0 0 24 669 3
Outcome: present
Updated model (risk categories)
Initial model (risk categories) (0, 0.01) (0.01, 0.05) (0.05, 0.1) (0.1, 1) % reclassified
(0, 0.01) 0 0 0 0 -
(0.01, 0.05) 0 4 1 0 20
(0.05, 0.1) 0 1 16 1 11
(0.1, 1) 0 0 1 233 0
Combined data
Updated model (risk categories)
Initial model (risk categories) (0, 0.01) (0.01, 0.05) (0.05, 0.1) (0.1, 1) % reclassified
(0, 0.01) 0 0 0 0 -
(0.01, 0.05) 0 57 3 0 5
(0.05, 0.1) 0 13 159 14 15
(0.1, 1) 0 0 25 902 3
Net-reclassification improvement (NRI) (categorical) (95 % CI): 0.0229 (0.0014, 0.0445); p value 0.03697. NRI (continuous) (95 % CI): 0.308 (0.1739, 0.4421);
p value: 0.00001. Integrated discrimination improvement (95 % CI): 0.015 (0.006, 0.024); p value: 0.00107. Reclassification table of the model without (initial) and
with (updated) growth-differentiation factor-15 (GDF-15) as a predictor of cardiac-surgery-associated acute kidney injury (CSA-AKI). The addition of GDF-15 in the
logistic regression model significantly improved prediction of the development of CSA-AKI.
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patients with diabetes mellitus also have increased
GDF-15 [22] and high risk of AKI after cardiac surgery
[1, 5]. It is of note that the number of patients with
diabetes mellitus in the present study in the highest
GDF-15 tertile was almost twice as high than in the
lowest GDF-15 tertile.
As a last and more general point, it has to be taken
into account that a preoperative score or biomarker will
never be able to perfectly predict a multifactorial com-
plication like CSA-AKI, because unpredictable intraop-
erative and postoperative factors, like unexpected
prolongation of surgery or prolonged mechanical venti-
lation [6], may render any prediction model - at least
partially - imprecise.
Conclusions
In conclusion and taking into account the limitations of
a monocentric study, but supporting findings from pre-
vious work in patients undergoing CABG [8, 9], the
present analysis shows that preoperative plasma GDF-15
is an independent predictor of postoperative AKI in pa-
tients undergoing elective cardiac surgery, and improves
the predictive ability of the CC-ARF score as an estab-
lished renal risk score and of logistic regression models
based on the additive Euroscore, age, duration of CPB,
and diabetes mellitus. Additionally, this biomarker seems
to be particularly helpful for further risk stratification
beyond accepted risk factors, i.e., especially in patients
with low preoperative creatinine.
Key messages
 Acute kidney injury (AKI) is a serious and frequent
complication in patients undergoing cardiac surgery
 Growth-differentiation factor-15 (GDF-15) is a
cytokine expressed upon myocardial stretch and
volume overload, and during oxidative stress and
ischemia/reperfusion
 GDF-15 has been shown to be reflective of poor
prognosis in various clinical settings, including heart
failure, myocardial infarction, and in patients
undergoing cardiac surgery
 The present study shows that preoperative plasma
GDF-15 is an independent predictor of postoperative
AKI in patients undergoing elective cardiac surgery
and improves the predictive ability of the established
renal risk score, the Cleveland Clinic Acute Renal
Failure score and of an individual logistic regression
model based on the additive Euroscore, age, duration
of CPB, and diabetes mellitus
Additional files
Additional file 1: Logistic regression model specification for 30 day
mortality. (DOCX 27 kb)
Additional file 2: Figure S1. Visualization of the predictive ability of
each input variable on the development of Cardiac Surgery-associated
Acute Kidney injury (CSA-AKI) (random forest model). Variables with
greater predictive ability (growth-differentiation factor-15 (GDF-15), age)
exhibit high variable importance and low minimal variable depth, whereas
Fig. 5 Recursive partitioning using conditional inference trees. Starting from the top, important variables and their respective cutoffs are presented
leading (bottom) to the percentage of patients (within each population partition) developing cardiac-surgery-associated acute kidney injury (CSA-AKI).
For example, from the group of patients with additive Euroscore <5 and growth-differentiation factor-15 (GDF-15) <1.271 ng/ml, 10 % developed
CSA-AKI (Node 3), whereas from the group of patients with additive Euroscore <5 and GDF-15 > 1.271 ng/ml, 20 % of patients developed CSA-AKI
(Node 4). CPB cardiopulmonary bypass
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variables less associated with CSA-AKI (diabetes) exhibit low variable importance
and high minimal depth. (TIFF 2787 kb)
Additional file 3: Figure S2. Covariate plot of the predictions from the
random forest model. Four variables are displayed. Within each box, the
x-axis denotes plasma creatinine (μmol/l), the y-axis the probability of
developing cardiac-surgery-associated acute kidney injury (CSA-AKI).
Within each column of plots, the additive Euroscore increases from bottom
to top (legend, right). Within each row of plots the growth-differentiation
factor-15 (GDF-15) levels increase from left to right. Significant non-linear
interaction takes place between GDF-15 and creatinine. Within each additive
Euroscore category (row of plots), increases in GDF-15 (plots more to the
right within each row) increase the probability of developing CSA-AKI.
However, this effect is more prominent in patients with normal creatinine
(x-axis label of each plot). (TIFF 3197 kb)
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